Repros (RPRX) Up 2%+ Following 'Statistically Significant' Androxal Data
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics Inc. (Nasdaq: RPRX) shares up 2.6 percent in late Thursday trading after reporting that Androxal achieved statistically significant versus a placebo in ZA-203 Phase 2b clinical study of Androxal in secondary hypogonadal men with moderate to severe dysfunction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma (RPRX) PT Raised to $62 at JPMorgan
- Pacira publishes two-year Phase 1 data for knee OA gene therapy
- Neurocrine starts Phase 1 trial of obesity drug NBIP-1968
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
